India to Cote D Ivoire Pharmaceutical Export

The pharmaceutical trade between India and Côte d'Ivoire has experienced significant growth from 2022 to 2026. In 2022, the total export value was $8.5 million USD, increasing to $12.3 million USD in 2023, $14.7 million USD in 2024, $16.5 million USD in 2025, and reaching $17.8 million USD in 2026. This upward trajectory reflects a compound annual growth rate (CAGR) of approximately 15%. Key milestones include the establishment of the National Drug Regulatory Authority (WHO-GMP) in Côte d'Ivoire in August 2017, which streamlined regulatory processes and enhanced the quality assurance of imported pharmaceutical products. Additionally, the implementation of the Trade Facilitation Agreement (TFA) in December 2015 has improved customs procedures, further facilitating trade between the two nations.

India has solidified its position as a leading supplier of pharmaceutical products to Côte d'Ivoire. In 2026, Indian pharmaceutical exports accounted for approximately 35% of Côte d'Ivoire's total pharmaceutical imports, surpassing other origins such as China and the European Union. This dominance is attributed to India's competitive pricing, adherence to WHO-GMP standards, and a diverse product portfolio that aligns with Côte d'Ivoire's healthcare needs.

Between 2024 and 2026, several developments have influenced the India-Côte d'Ivoire pharmaceutical trade. In March 2024, a bilateral trade agreement was signed, reducing tariffs on pharmaceutical imports and enhancing market access. In July 2025, the Ivorian government implemented a new regulatory framework for pharmaceutical imports, aligning with international standards and expediting approval processes. These initiatives have further strengthened the trade relationship and facilitated smoother market entry for Indian pharmaceutical companies.

Indian pharmaceutical companies seeking to register products in Côte d'Ivoire must comply with the requirements set by the National Drug Regulatory Authority (WHO-GMP). The registration dossier should include:

• Certificate of Good Manufacturing Practices (GMP) valid in two copies, issued by the competent authority of the country of origin.

• Valid Manufacturing Establishment License, issued by the Competent Authority of the country of origin.

• The master file of the finished product manufacturing site (electronic version only).

• The Summary of Product Characteristics (SPC) according to the model available on the AIRP website in French, in Word or in editable PDF.

The registration process typically takes 6 to 12 months, depending on the completeness of the submitted documentation and the efficiency of the regulatory authority.

Côte d'Ivoire mandates that manufacturing sites adhere to WHO-GMP standards. The inspection process involves a comprehensive evaluation of the facility's compliance with these standards, including quality control measures, production processes, and documentation practices. Mutual recognition agreements between India and Côte d'Ivoire facilitate the acceptance of GMP certifications issued by recognized authorities, streamlining the approval process for Indian manufacturers.

Importers in Côte d'Ivoire must obtain an Official Import Authorization (OIA) for pharmaceutical products. The required documentation includes:

• Import authorization application letter in two copies.

• Two copies of the invoice showing:

• The name and address of the supplier (shipper).

• The name and address of the importing entity (consignee); the applicant must be the consignee.

• The invoice number and date.

• The description (trade name + INN where applicable) and quantity of the products.

• The batch number.

• The date of manufacture and expiry date, where applicable (in the case of products with a short expiry date).

Additionally, a Preliminary Import Authorization (API) is required for medicines, parapharmaceutical products, medical promotional material, medical and surgical equipment, laboratory materials and reagents, optical and eyewear equipment, chemicals, raw materials for the manufacture of medicines, primary packaging articles for medicines, semi-finished products, blood products, biological fluids, and organs. (gucecotedivoire.ci)

India's pharmaceutical exports to Côte d'Ivoire are predominantly in the antiretroviral (ARV) segment, addressing the high prevalence of HIV/AIDS in the region. The top three products exported include:

1. Dolutegravir Sodium 10mg Scored Dispersible Tablet for Oral Suspension (1x90's) (10,000 Pack) ($3.9M, 8.6%).

2. DLT (Dolutegravir, Lamivudine, and Tenofovir) Combination Tablets ($2.3M, 5.2%).

3. Viropil 50/300/300mg Tablet 90s WTC (Dolutegravir, Lamivudine, and Tenofovir) ($1.6M, 3.6%).

These products align with Côte d'Ivoire's healthcare priorities, reflecting a strategic focus on combating HIV/AIDS.

The expiration of patents for several blockbuster drugs presents opportunities for Indian pharmaceutical companies to introduce generic versions in Côte d'Ivoire. Additionally, the growing demand for biosimilars offers a promising avenue for market expansion. Therapeutic areas such as oncology and diabetes management are emerging as potential growth segments for Indian exporters.

Côte d'Ivoire's high disease burden, particularly in HIV/AIDS, malaria, and tuberculosis, drives the demand for affordable and effective pharmaceutical products. The aging population and increasing healthcare spending further contribute to the rising import demand from India. Government initiatives aimed at improving healthcare infrastructure and access to medicines also play a significant role in boosting pharmaceutical imports.

Côte d'Ivoire applies a 0% duty on essential social goods, including pharmaceutical products. However, additional charges such as the Community Levy of Solidarity (PCS) at 1% and the ECOWAS community levy at 0.5% of the CIF value are applicable. Value Added Tax (VAT) is levied at a rate of 18% on the CIF value plus the entry duty and statistical fee.

Côte d'Ivoire is a member of the West African Economic and Monetary Union (WAEMU) and the Economic Community of West African States (ECOWAS), which influence trade policies and agreements. The Trade Facilitation Agreement (TFA), ratified in December 2015, aims to simplify customs procedures and enhance trade efficiency. Ongoing negotiations within these frameworks may impact pharmaceutical trade dynamics.

Côte d'Ivoire adheres to international intellectual property agreements, including the Trade-Related Aspects of Intellectual Property Rights (TRIPS). Patent provisions, data exclusivity, and compulsory licensing are in place, affecting the entry of Indian generic products. Indian exporters must navigate these regulations to ensure compliance and protect their intellectual property rights.

Pharmaceutical shipments from India to Côte d'Ivoire primarily utilize sea routes, with major ports including Nhava Sheva Sea (INNSA1) and JNPT in India, and Abidjan in Côte d'Ivoire. Air freight is also utilized, with Bangalore Air serving as a key export port. Transit times vary depending on the mode of transport and specific routes chosen.

In India, Nhava Sheva Sea (INNSA1) and JNPT are the primary export ports, handling a significant volume of pharmaceutical exports. In Côte d'Ivoire, Abidjan serves as the main import port, accounting for approximately 93.6% of pharmaceutical imports. The port's infrastructure supports efficient handling and distribution of pharmaceutical products. (gucecotedivoire.ci)

Maintaining the integrity of pharmaceutical products during transit is critical. Both India and Côte d'Ivoire adhere to Good Distribution Practice (GDP) guidelines, ensuring temperature-controlled logistics and compliance with packaging standards. Exporters must coordinate with logistics providers to meet these requirements, safeguarding product quality upon arrival.

Côte d'Ivoire's pharmaceutical market has been expanding, with an estimated value of $200 million USD in 2026, growing at a rate of 10% annually. The